Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
Go back to Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 199.71 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $199.71 | 52 Week High | $333.65 | |||
| Open | $199.71 | 52 Week Low | $223.02 | |||
| Day High | $199.71 | P/E | 25.57 | |||
| Day Low | $199.71 | EPS | $7.81 | |||
| Volume | 2,261 | |||||
